Navigation Links
ViroPharma to Participate in Two June Healthcare Investor Conferences
Date:6/3/2010

EXTON, Pa., June 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Jefferies 2010 Global Life Sciences Conference at 4:00 P.M. ET on Wednesday, June 9, 2010.  The conference is being held at the Grand Hyatt in New York City.

Mr. Roberts also will present at the ThinkEquity Healthcare Conference at 1:30 P.M. ET on Wednesday, June 16, 2010.  The conference is being held at the Princeton Club in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma To Host Investor Day
2. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
4. Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
5. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
6. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
7. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
11. ViroPharma Announces Discontinuation of HCV-796 Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... --  Fourth-quarter 2016 revenues of ... to top end of guidance ... in fourth-quarter 2016 associated with the write-down of goodwill ... reporting unit Fourth-quarter reported ... Full-year 2016 reported $14.48 diluted (GAAP) loss per share ...
(Date:2/27/2017)... 27, 2017 Mederi Therapeutics today announced ... representing 2468 patients who received  Stretta Therapy  to ... " Systematic Review and Meta-Analysis of Controlled and ... Treatment of Gastroesophageal Reflux Disease ", was published in ... Fass , MD, head of the Esophageal and ...
(Date:2/27/2017)... Feb. 27, 2017   Vitasome ® Labs ... supplements using its groundbreaking new liposome technology. Whereas vitamins ... potency through digestion per Physician,s Desk Reference , ... problem of nutritional waste and are scientifically formulated to: ... processes Improve bioavailability with a vastly ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... , ... BrightStar Care Marietta announced that it has received the 2017 Best ... is granted only to top-ranking home care providers, based on client satisfaction scores gathered ... care providers from across the country who have proven their ability to provide the ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... care industry, announces Chris Brandl as its New Guest Director. , Brandl ... to corporations throughout his career. He began his professional career at Omnium Worldwide, ...
(Date:2/27/2017)... Ohio (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your ... Life” to studying to become a nun. Now, she writes about God, when she isn’t ... “You Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):